



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 72483

**Title:** Assessment of circulating levels microRNA-326, microRNA-424, and microRNA-511 as Biomarker for hepatocellular carcinoma in Egyptians

**Provenance and peer review:** Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 01221925

**Position:** Editorial Board

**Academic degree:** AGAF, FACS, FICS, MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Greece

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2021-10-22

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-10-23 08:49

**Reviewer performed review:** 2021-10-24 18:50

**Review time:** 1 Day and 10 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### **SPECIFIC COMMENTS TO AUTHORS**

This is an interesting paper presenting the prevalence and potential role of three different MiRNAs regarding HCC in an Egyptian population. Could the authors please respond to the following questions/comments? 1) Why did the authors choose only patients with HCV related liver cirrhosis? 2) Also for controls did the authors consider patients with cirrhosis but without HCC and also patients with HCC but without cirrhosis? 3) What kind of HCV treatment had those patients received currently and in the past? 4) The authors, given the fact that all their patients were HCV-HCC, should perhaps rephrase the conclusion so that it has to do with the specific subset of patients 5) What treatments did these patients receive?



## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 72483

**Title:** Assessment of circulating levels microRNA-326, microRNA-424, and microRNA-511 as Biomarker for hepatocellular carcinoma in Egyptians

**Provenance and peer review:** Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05224602

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Doctor, Professor

**Reviewer's Country/Territory:** China

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2021-10-22

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-11-25 01:26

**Reviewer performed review:** 2021-12-07 05:16

**Review time:** 12 Days and 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input checked="" type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
-------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### **SPECIFIC COMMENTS TO AUTHORS**

In their report, the authors assessed the role of circulating miRNAs326, miRNA-424 and miRNA-511 in Egyptian HCC patients. They show that miRNAs326, miRNA-424 and miRNA-511 could have diagnostic and prognostic roles in Egyptian HCC patients and should be considered for better management of the disease. However, the similar results were reported in several papers, including PMID: 28060739, PMID: 26927063. Therefore, the current status of the manuscript is not full of sufficient novelty, and not meet the criteria of a high quality World Journal of Gastroenterology paper.



## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Hepatology*

**Manuscript NO:** 72483

**Title:** Assessment of circulating levels microRNA-326, microRNA-424, and microRNA-511 as Biomarker for hepatocellular carcinoma in Egyptians

**Provenance and peer review:** Invited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 01221925

**Position:** Editorial Board

**Academic degree:** AGAF, FACS, FICS, MD, PhD

**Professional title:** Professor

**Reviewer's Country/Territory:** Greece

**Author's Country/Territory:** Egypt

**Manuscript submission date:** 2021-10-22

**Reviewer chosen by:** Yu-Jie Ma

**Reviewer accepted review:** 2022-02-25 19:13

**Reviewer performed review:** 2022-02-25 19:14

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
**https://**www.wjgnet.com

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

I would like to thank the authors for their responses and the changes made accordingly